Bradley Foster & Sargent Inc. CT Increases Stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Bradley Foster & Sargent Inc. CT grew its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 2,000.7% in the 4th quarter, Holdings Channel reports. The institutional investor owned 88,713 shares of the company’s stock after purchasing an additional 84,490 shares during the quarter. Bradley Foster & Sargent Inc. CT’s holdings in IDEXX Laboratories were worth $36,678,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in IDXX. Whittier Trust Co. boosted its stake in IDEXX Laboratories by 10.1% during the 3rd quarter. Whittier Trust Co. now owns 1,673 shares of the company’s stock valued at $845,000 after purchasing an additional 153 shares during the last quarter. Eastern Bank purchased a new stake in shares of IDEXX Laboratories during the third quarter valued at $90,000. Lecap Asset Management Ltd. purchased a new stake in shares of IDEXX Laboratories during the third quarter valued at $419,000. Commerzbank Aktiengesellschaft FI raised its position in IDEXX Laboratories by 25.7% in the 3rd quarter. Commerzbank Aktiengesellschaft FI now owns 656 shares of the company’s stock worth $332,000 after buying an additional 134 shares during the last quarter. Finally, International Assets Investment Management LLC raised its position in IDEXX Laboratories by 52,746.0% in the 3rd quarter. International Assets Investment Management LLC now owns 528,460 shares of the company’s stock worth $2,669,890,000 after buying an additional 527,460 shares during the last quarter. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Performance

NASDAQ:IDXX opened at $452.89 on Friday. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31. The stock has a 50-day simple moving average of $431.50 and a two-hundred day simple moving average of $452.42. The firm has a market capitalization of $37.09 billion, a PE ratio of 42.45, a P/E/G ratio of 3.39 and a beta of 1.37. IDEXX Laboratories, Inc. has a 52-week low of $398.50 and a 52-week high of $583.39.

Insider Activity at IDEXX Laboratories

In other IDEXX Laboratories news, Director M Anne Szostak sold 3,000 shares of the company’s stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the transaction, the director now directly owns 3,061 shares in the company, valued at $1,426,242.34. This represents a 49.50 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Sophie V. Vandebroek sold 344 shares of the firm’s stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total transaction of $144,631.36. Following the sale, the director now owns 905 shares in the company, valued at $380,498.20. The trade was a 27.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 13,330 shares of company stock worth $6,161,276. 2.11% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. Piper Sandler raised their price target on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a report on Monday, February 10th. Morgan Stanley dropped their target price on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a report on Wednesday, January 29th. Barclays boosted their target price on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a research note on Tuesday, February 4th. Leerink Partners assumed coverage on IDEXX Laboratories in a research note on Monday, December 2nd. They issued an “outperform” rating and a $500.00 price target on the stock. Finally, Bank of America upped their price objective on IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a research report on Tuesday, February 4th. Four investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, IDEXX Laboratories presently has an average rating of “Moderate Buy” and an average target price of $533.75.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.